Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(9 years from now) | |
US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(9 years from now) | |
US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(8 years from now) | |
US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(8 years from now) | |
US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(8 years from now) | |
US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(8 years from now) | |
US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(9 years from now) | |
US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(9 years from now) | |
US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(9 years from now) | |
US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(11 years from now) | |
US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(12 years from now) | |
US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(12 years from now) | |
US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 23, 2025 |
New Indication (I) | Jun 18, 2023 |
Orphan Drug Exclusivity (ODE) | Jan 23, 2027 |
NCE-1 date: 2024-01-24
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an...
Dosage: TABLET;ORAL
73
United States
27
Japan
22
Korea, Republic of
21
Australia
18
Israel
18
European Union
16
China
13
Canada
11
Russia
10
Singapore
9
Denmark
9
Spain
9
Brazil
8
New Zealand
8
Poland
8
Hungary
7
Portugal
7
Mexico
6
Croatia
6
Slovenia
6
RS
6
Lithuania
5
Hong Kong
3
Peru
3
Chile
3
Cyprus
3
Ukraine
3
Philippines
3
South Africa
3
Taiwan
2
EA
2
Malaysia
2
Jordan
2
Argentina
1
India
1
ME
1
San Marino
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic